- Details
- Hits: 926
The resurgence of psychedelics in the United States has reignited fierce debates about their safety, efficacy, and the ethical concerns surrounding their use in mental health treatment. Once dismissed as dangerous hallucinogens associated with counterculture movements, substances like MDMA and psilocybin are now being promoted as potential therapies for mental health disorders. But despite the rising enthusiasm, serious risks and controversies overshadow the movement’s credibility.
Recent developments have exposed significant flaws in the drive to legitimise psychedelics as a medical treatment. Leading the charge has been the Multidisciplinary Association for Psychedelic Studies (MAPS), founded by Rick Doblin. For years, MAPS championed MDMA, also known as “ecstasy,” as a treatment for post-traumatic stress disorder (PTSD), claiming it could help trauma survivors where traditional therapies had failed. However, these bold claims met resistance in August when the US Food and Drug Administration (FDA) rejected MAPS’s application to approve MDMA for PTSD treatment. The FDA cited unresolved safety concerns and demanded more rigorous research—raising alarm bells about potential harm to vulnerable patients.
Among the issues flagged was the problem of “functional unblinding” in clinical trials. Participants who took MDMA often recognised its effects compared to those given a placebo, potentially biasing the results. Critics argue that such methodological weaknesses undermine the reliability of the findings, making it difficult to separate genuine therapeutic benefits from placebo effects. Additionally, reports of trial participants suffering adverse side effects, including increased suicidal thoughts, cast further doubt on the safety of MDMA in a clinical context.
The lack of robust regulation within the psychedelic movement has also come under fire. Allegations of misconduct during therapy sessions, including inappropriate behaviours by therapists, have been particularly troubling. These incidents suggest that in the rush to advocate psychedelics, the movement has overlooked essential safeguards. Ethical practices have been questioned as some researchers and therapists appear more aligned with the movement’s countercultural roots than with professional medical standards.
From a scientific standpoint, the evidence supporting the use of psychedelics remains alarmingly weak. A Cochrane Review, known for its rigorous analysis of clinical research, assessed psychedelic studies and rated the quality of evidence as “low to very low.” Serious adverse events, including hospitalisations and even fatalities, have been documented in individuals with pre-existing mental health conditions—the very group these treatments are intended to help. These findings underscore the need for extreme caution when considering psychedelics as an alternative to established therapies.
The cultural aspect of the movement further complicates its acceptance within mainstream medicine. Psychedelics are often promoted in a utopian, almost evangelical manner, with supporters touting them as groundbreaking solutions to mental health challenges. However, this fervour risks undermining the scientific objectivity required to evaluate such treatments. For critics, the movement’s idealistic approach appears reckless, prioritising ideology over patient safety and scientific integrity.
The FDA’s rejection of MDMA has prompted some within the movement to re-evaluate their approach. Both Rick Doblin and Lykos Therapeutics’ CEO have stepped down, signalling efforts to professionalise the field and align it more closely with the standards of pharmaceutical regulation. Despite this, the question remains whether the psychedelic industry can overcome its legacy of countercultural enthusiasm and deliver on its promises in a safe, evidence-based manner.
Ultimately, the psychedelic movement’s push for medical legitimacy presents a stark warning about the dangers of rushing experimental treatments into practice. Psychedelics, if mishandled, could not only harm vulnerable individuals but also undermine trust in scientific and psychiatric advances. Until rigorous trials and clear ethical boundaries are established, these substances remain a highly risky proposition, raising more concerns than they answer in the complex landscape of mental health care.
(Source: WRD News)
- Details
- Hits: 693
Recent developments in psychedelic research have brought to light significant concerns regarding the integrity and safety of studies focused on these substances. Once hailed as a potential breakthrough in mental health treatment, psychedelics are now facing scrutiny due to issues surrounding research practices and the portrayal of their efficacy.
Scientific Integrity Under Scrutiny
The allure of psychedelics as a promising treatment for mental health conditions like depression and PTSD has sparked widespread interest and investment. However, recent reports suggest that the enthusiasm for these substances may have overshadowed the rigour required in scientific research. Studies often suffer from small sample sizes and lack of proper blinding, which undermines the reliability of their findings. Additionally, the influence of researchers’ personal beliefs has been noted, potentially skewing results and leading to the underreporting of adverse side effects. As noted by The New York Times, “The F.D.A.’s rejection signals greater uncertainty for the future of psychedelic medicine. And it will take more than just additional clinical trials for advocates to get back on track — it might require changing the culture of the research community from within”.
Ethical Concerns and Public Perception
The portrayal of psychedelics as a safe and effective treatment option has been challenged by recent incidents highlighting the risks associated with their use. Cases of inadequate reporting of negative outcomes, such as increased suicidality in some trial participants, underscore the need for cautious interpretation of the available data. The romanticised view of psychedelics, sometimes driven by prominent figures in the field, risks misleading the public and overshadowing the potential dangers these drugs can pose….
- Details
- Hits: 932
Recent research highlights the surprising similarities between smoking and vaping concerning their impact on DNA, challenging the notion that vaping is a safer alternative to smoking. The study, conducted by researchers at the University of Southern California (USC), provides critical insights into how both habits can lead to harmful genetic changes that may contribute to disease development, including cancer.
Study on DNA Methylation: The study focused on DNA methylation, a process that acts as an on/off switch for genes. Researchers examined the genomes of young adults who were either exclusive smokers, vapers, or neither. Using high-tech gene sequencing on cheek swab samples, the study identified 831 differentially methylated regions (DMRs) in the genomes of vapers and 2,863 in smokers. Remarkably, there was a 46% overlap in DMRs between smokers and vapers, suggesting similar genetic alterations occur in both groups.
Implications for Public Health: The findings have profound implications for public health, especially regarding the regulation of vaping products. “These findings indicate that the changes in DNA methylation observed in vapers may contribute to the development of disease, including cancer,” said Stella Tommasi, the study’s lead author and an associate professor at USC. The research underscores the need to keep vaping products away from young people, who are particularly vulnerable to these genetic changes.
The Role of the HIC1 Gene: A significant discovery from the study was the identification of a methylation change in the HIC1 gene, a known tumour suppressor. Changes in this gene have long been associated with lung cancer, indicating that similar carcinogenic processes may occur in young adults who vape. “Electronic cigarettes are not as safe as some people claim, even if the level of most toxicants and carcinogens present in e-liquid and vapour is generally much lower than that found in cigarette smoke,” Tommasi noted. This finding could significantly boost research efforts into understanding the health risks of vaping.
Comparison Between Smokers and Vapers: The study provides a detailed comparison of the genetic impacts of smoking and vaping. While smoking has a more extensive array of identified DMRs, the genetic overlap with vaping suggests that both practices can lead to similar unhealthy changes in DNA. This overlap challenges the perception that vaping is a harmless alternative, emphasising the need for caution and further research into its long-term health effects.
Potential Health Risks Associated with Vaping: The research highlights that vaping may not be the safe alternative it is often portrayed as, given its potential to cause similar genetic changes associated with smoking-related diseases. The methylation changes observed in both vapers and smokers could drive disease development, raising concerns about the long-term health implications for young users who may be unaware of these risks.
The study’s insights into DNA methylation underline the importance of informed public health strategies to address the risks associated with vaping and smoking. As vaping gains popularity among young adults, understanding its genetic impacts is crucial for shaping effective health policies and prevention programs.
(Source: US News)
- Details
- Hits: 867
E-cigarette use among adolescents has become a widespread public health concern. Despite the known harms of nicotine exposure, there has been a lack of empirically tested interventions aimed at helping teens quit vaping. A recent randomised clinical trial investigated the effectiveness of a tailored, interactive text message program designed to promote vaping cessation among adolescents.
Study Design and Participants
The study was a parallel, two-group, double-blind, individually randomised clinical trial conducted from October 1, 2021, to October 18, 2023. It included 1,503 adolescent e-cigarette users aged 13 to 17 years who were interested in quitting vaping within 30 days. Participants were recruited via social media ads and were required to own a mobile phone with an active text message plan. The intervention was delivered via text message, and assessments were completed online or by telephone.
Interventions
Participants were divided into two groups:
- Assessment-Only Control Group (n=744): This group received only study retention text messages.
- Intervention Group (n=759): In addition to receiving study retention text messages, this group received a tailored, automated, interactive text message program designed to deliver cognitive and behavioural coping skills training and social support.
Primary Outcome Measure
The primary outcome of the study was self-reported 30-day point-prevalence abstinence from vaping at seven months. This was analysed using intention-to-treat analysis, with any missing data coded as continued vaping.
Results
The trial achieved a 70.8% retention rate at seven months. The intention-to-treat analysis revealed the following abstinence rates:
- Intervention Group: 37.8% of participants reported abstinence from vaping.
- Assessment-Only Control Group: 28.0% of participants reported abstinence from vaping.
This difference was statistically significant (P < .001). Importantly, no baseline characteristics, including nicotine dependence, moderated the treatment-outcome relationship. Additionally, there was no evidence that adolescents who quit vaping transitioned to combustible tobacco products.
Implications
The study demonstrated that a tailored, interactive text message program significantly increased self-reported vaping cessation rates among adolescents. This finding is crucial given the high prevalence of e-cigarette use among teens and the associated health risks. The success of this intervention highlights the potential of using digital health tools to support adolescent vaping cessation.
This randomised clinical trial provides strong evidence that a tailored text message program can effectively help adolescents quit vaping. Given the high rates of e-cigarette use among teens and the lack of empirically tested cessation interventions, this study underscores the importance of developing and implementing innovative digital health solutions to address this public health challenge.
(Source: JAMA)
- Dual Vaping and Smoking Quadruples Lung Cancer Risk
- Growing Scepticism Towards Psychedelic Science: The Low Voltage ‘Surge’ of Problematic Research
- New Laws for Vapes – AUSTRALIA
- Pill Testing: A comprehensive series on Pill Checking/Testing – Get the facts, not the spin. A must read for all Australians, from Politician to Parent to Punter.
